rs141864044
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BS2BP2
This summary comes from the ClinGen Evidence Repository: The c.1174G>A variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). This variant was observed in trans with a known pathogenic CDH1 variant (phase unknown) and observed in the homozygous state in gnomAD v2.0.2 (BP2; internal laboratory contributor and gnomAD). Therefore, the clinical significance of this variant is likely benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2, BP2. LINK:https://erepo.genome.network/evrepo/ui/classification/CA288019/MONDO:0007648/007
Frequency
Consequence
NM_004360.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDH1 | NM_004360.5 | c.1174G>A | p.Val392Ile | missense_variant | Exon 9 of 16 | ENST00000261769.10 | NP_004351.1 | |
CDH1 | NM_001317185.2 | c.-442G>A | 5_prime_UTR_variant | Exon 9 of 16 | NP_001304114.1 | |||
CDH1 | NM_001317186.2 | c.-646G>A | 5_prime_UTR_variant | Exon 9 of 15 | NP_001304115.1 | |||
CDH1 | NM_001317184.2 | c.1137+1086G>A | intron_variant | Intron 8 of 14 | NP_001304113.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000592 AC: 9AN: 152132Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000135 AC: 34AN: 251470Hom.: 0 AF XY: 0.000155 AC XY: 21AN XY: 135906
GnomAD4 exome AF: 0.0000773 AC: 113AN: 1461880Hom.: 0 Cov.: 32 AF XY: 0.0000908 AC XY: 66AN XY: 727244
GnomAD4 genome AF: 0.0000591 AC: 9AN: 152250Hom.: 0 Cov.: 32 AF XY: 0.0000806 AC XY: 6AN XY: 74442
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Benign:4
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
- -
- -
Hereditary diffuse gastric adenocarcinoma Benign:2
- -
BS2; BP2 (PMID: 30311375) -
not provided Benign:2
- -
- -
not specified Benign:1
Variant summary: CDH1 c.1174G>A (p.Val392Ile) results in a conservative amino acid change located in the Cadherin-like domain (IPR002126) of the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00014 in 251470 control chromosomes. The observed variant frequency is approximately 4.78 fold of the estimated maximal expected allele frequency for a pathogenic variant in CDH1 causing Hereditary Diffuse Gastric Cancer phenotype (2.8e-05), strongly suggesting that the variant is benign. Although observed in the literature, to our knowledge, no occurrence and/or penetrant association of c.1174G>A in individuals affected with Hereditary Diffuse Gastric Cancer/Lobular Breast Cancer and no experimental evidence demonstrating its impact on protein function have been reported. Nine submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as benign. -
Familial cancer of breast;C1140680:Ovarian cancer Benign:1
- -
CDH1-related diffuse gastric and lobular breast cancer syndrome Benign:1
The c.1174G>A variant has been observed in >10 individuals without a diagnosis of diffuse gastric cancer, signet ring tumor or lobular breast cancer and whose family histories do not suggest HDGC (BS2; internal laboratory contributors). This variant was observed in trans with a known pathogenic CDH1 variant (phase unknown) and observed in the homozygous state in gnomAD v2.0.2 (BP2; internal laboratory contributor and gnomAD). Therefore, the clinical significance of this variant is likely benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BS2, BP2. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at